Survey of Toxicity Assess & Reporting

Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer.

Perrone F, De Maio E, Maione P, Di Maio M, Ottaiano A, Pensabene M, Di Lorenzo G, Vernaglia Lombardi A, Gallo CClinical Trials Office, National Cancer Institute. [Medline record in process]

PURPOSE: To review how toxicity, a main end point of phase II studies, is assessed and reported in published phase II chemotherapy trials in breast cancer.

METHODS: A survey was performed by hand-searching studies published in seven distinguished journals between 1995 and 1999. All selected articles were independently evaluated by two investigators using an ad hoc study report form. Descriptive statistics, contingency tables, and the chi(2) test were applied. p

RESULTS: Overall, 122 articles were found; 65.6% lacked a statistical study design. Planned modalities for assessment of toxicity were inadequately reported in 20.5% of the studies. The scheduling of assessment of hematologic toxicity varied greatly. Toxicity was predominantly summarized per patient (69.7%).

Although overall the World Health Organization scale was adopted more frequently (45.9%), the Common Toxicity Criteria (in different versions) were used more frequently in studies published in journals with a high impact factor (P =.001), in more recently initiated studies (P =.03), in sponsored studies (P =.0006), and in studies with an identifiable statistical design (P =.006).

CONCLUSION: The wide diversity in modalities of toxicity assessment and reporting observed in this study suggests that the reliability of the body of published data on the toxicity of chemotherapy in breast cancer may be questionable.

Current standards should be revised and harmonized to improve the reliability of such data. A checklist is proposed to help editorial evaluation of assessment and reporting of toxicity in phase II studies.

J Clin Oncol 2002 Jan 1;20(1):52-7 PMID: 11773153, UI: 21635056


Unable to Eat Due to Treatment

CNN Story, 4/17/02

Unwanted Effects From Anti-Nausea/Vomiting Drugs

The Oncologist, 10/02

Documented Allergies in People w/Cancer

Eur J Cancer Care, 12/03

Dexamethasone Reduces Paclitaxel/Doxorubicin Effects

Cancer Res, 3/04

Desensitization from Hypersensitivity Reactions to Chemo

Curr Opin Allergy Clin Immunol, 8/08

Epidermal Grwth Factor Rcptor Inhibitor–Assoctd Cutaneous Toxicities:

The Oncologist, May 2007


Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.